{"entity":{"id":"nct06198751","kind":"trial","name":"A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","aka":[],"tldr":"A phase 2 trial of TQB2102 in HER2-positive breast cancer, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., active and no longer recruiting.","summary":"A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer is a phase 2 interventional study registered as NCT06198751 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 104 participants enrolled, started 2024-02-05 and due to reach its primary completion in 2025-05-08. Interventions recorded: 6.0 mg/kg of TQB2102 for injection and 7.5 mg/kg of TQB2102 for injection.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06198751","url":"https://clinicaltrials.gov/study/NCT06198751"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-her2-positive","her2-positive-early-breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["tqb2102"],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct06198751-j-clin-oncol-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06198751","phase":"2","setting":"A Phase 2, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of TQB2102 for Injection for Neoadjuvant Treatment of Breast Cancer With Positive HER2 Expression","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","started":"2024-02-05","startedType":"actual","enrolled":104,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06198751/","neighbours":{"cancer":[{"id":"her2-positive-early-breast-cancer","kind":"cancer","name":"Early HER2-positive breast cancer","route":"/cancers/her2-positive-early-breast-cancer/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"drug":[{"id":"tqb2102","kind":"drug","name":"TQB2102","route":"/drugs/tqb2102/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}],"paper":[{"id":"paper-nct06198751-j-clin-oncol-2026","kind":"paper","name":"Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial","route":"/key-papers/paper-nct06198751-j-clin-oncol-2026/"}]}}